Skip to content

Comparative Study of Intraarticular Erythropoietin and Dextrose in Knee Osteoarthritis

Comparative Study of Intraarticular Erythropoietin and Dextrose Prolotherapy in Knee Osteoarthritis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170910036107N8
Enrollment
42
Registered
2024-04-12
Start date
2024-05-21
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis.

Interventions

Intervention 1: Intervention group: Erythropoietin intraarticular injection. Under sterile conditions and after local anesthesia( 1 cc of lidocaine 2%), 4000 IU of erythropoietin is injected into th

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with 2 and 3 knee osteoarthritis according to Lawrence-Kellgren criteria knee pain for at least 6 months ages from 18 to 75 years old referring to the physical medicine department of Firuzgar and Rasul Akram hospitals.

Exclusion criteria

Exclusion criteria: absence of any acute or chronic infection not getting pregnant or not deciding to get pregnant not performed any intraarticular injection during last 3 months absence of inflammatory joint diseases or secondary osteoarthritis not having knee surgery not having severe underlying diseases such as uncontrolled DM not taking opioid or non-opioid analgesics not taking anticoagulants

Design outcomes

Primary

MeasureTime frame
VAS and Womac scores. Timepoint: before injection, 1 month and 3 months after injection. Method of measurement: VAS score is described by the patient and womac score with questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNaseh Usefi

Iran University of Medical Sciences

nasehusefi@gmail.com+98 21 8214 1612

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026